Supernus Pharmaceuticals (SUPN) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a hold rating to a buy rating in a research note released on Wednesday, January 10th. The brokerage currently has $46.00 target price on the specialty pharmaceutical company’s stock.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

A number of other research analysts have also recently weighed in on SUPN. Piper Jaffray Companies reiterated a hold rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. Cantor Fitzgerald reiterated a buy rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Jefferies Group reiterated a buy rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 20th. Cowen reiterated a buy rating and set a $50.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, September 21st. Finally, B. Riley reissued a buy rating and issued a $50.00 price target (down from $53.00) on shares of Supernus Pharmaceuticals in a research note on Monday, November 6th. Three equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Supernus Pharmaceuticals currently has a consensus rating of Buy and an average target price of $49.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded down $1.40 during mid-day trading on Wednesday, hitting $42.75. The stock had a trading volume of 746,600 shares, compared to its average volume of 589,510. Supernus Pharmaceuticals has a 1-year low of $23.10 and a 1-year high of $50.04. The firm has a market capitalization of $2,300.00, a P/E ratio of 38.86 and a beta of 1.17.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The firm had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company’s revenue was up 41.5% compared to the same quarter last year. equities analysts anticipate that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In related news, VP Victor Vaughn sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the sale, the vice president now directly owns 24,344 shares in the company, valued at approximately $1,023,421.76. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. Insiders sold a total of 125,750 shares of company stock worth $5,273,573 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Supernus Pharmaceuticals by 278.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC boosted its position in Supernus Pharmaceuticals by 91.4% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 1,462 shares during the period. Advisor Group Inc. boosted its position in Supernus Pharmaceuticals by 13.7% during the 2nd quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 410 shares during the period. Victory Capital Management Inc. boosted its position in Supernus Pharmaceuticals by 17.7% during the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after purchasing an additional 517 shares during the period. Finally, Flinton Capital Management LLC boosted its position in Supernus Pharmaceuticals by 88.9% during the 2nd quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 2,240 shares during the period. Institutional investors and hedge funds own 98.22% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Supernus Pharmaceuticals (SUPN) Stock Rating Upgraded by Zacks Investment Research” was first published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/supernus-pharmaceuticals-supn-upgraded-by-zacks-investment-research-to-buy/1822925.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets


Leave a Reply

 
© 2006-2018 BBNS.